Pharmafile Logo
Pharmafocus logo
Advanced Search

ovarian cancer

Showing 10 posts of 55 posts found.

astrazeneca image

AstraZeneca begins olaparib programme

September 4, 2013
Sales and Marketing AstraZeneca, olaparib, ovarian cancer

AstraZeneca has begun recruitment in its Phase III programme for olaparib, a potential first-in-class oral poly ADP ribose polymerase (PARP) …

News
Ovarian cells image

New ovarian cancer screening shows promise

August 27, 2013
Research and Development, Sales and Marketing ovarian cancer, screening

A new screening process for ovarian cancer is showing encouraging results, according to researchers in the US. In a trial …

News

Ovarian cancer charity wins GSK/King’s Fund award

May 21, 2012
Medical Communications, Sales and Marketing GSK, awards, charity, king's fund, ovarian cancer

A charity which aims to increase the chances of survival for patients with a poorly-treated form of cancer is to …

News

AstraZeneca posts drug failures, takes $382m hit

December 20, 2011
Research and Development, Sales and Marketing AstraZeneca, depression, ovarian cancer

AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …

News

Roche’s Avastin set for new ovarian cancer indication in Europe

September 26, 2011
Sales and Marketing avastin, ovarian cancer

Roche’s Avastin has gained the backing of European regulatory advisors for a new indication in ovarian cancer. The European Medicines …

News
Caribbean tunicate Ecteinascidia turbinata

NICE gives final no to PharmaMar’s Yondelis

April 27, 2011
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …

News
Yondelis - tunicate Ecteinascidia turbin

NICE rejects PharmaMar’s ovarian cancer drug Yondelis

March 14, 2011
Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer

NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …

News

Roche eyes ovarian cancer expansion for Avastin

February 8, 2011
Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer

Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …

News

Ovarian cancer trial boost for Avastin

July 5, 2010
Research and Development Roche, avastin, ovarian cancer

Roche’s blockbuster oncology drug Avastin has met its primary endpoint of improving progression-free survival in women with ovarian cancer in …

News
Ecteinascidia turbinata

NICE rejects Yondelis in ovarian cancer

June 21, 2010
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

New cancer treatment Yondelis has been rejected by NICE in a preliminary ruling on its use in relapsed ovarian cancer. …

News

Latest content

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024